MLLT3 and leukemia: To investigate whether the R domain mediates the response of MLL-AF9 leukemia cells to DOT1L-inhibitory treatment, we compared a pair of pooled survival tiling screens conducted under control (dimethyl sulfoxide (DMSO)) vs. DOT1L-inhibited (1 μM EPZ5676) conditions (Fig. 3a).